UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

~~CURRENT~~Current Report ~~REPORT~~Pursuant

~~Pursuant~~ to Section 13 ORor 15(d) of the

~~The~~ Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)~~: May~~ ~~9, 2007~~

SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware	0-26694	93-0945003
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
585 West 500 South Bountiful, Utah		84010
(Address of principal executive offices)		( (Zip Code)
Registrant’s telephone number, including area code (801) 298-3360

November 30, 2007

SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-26694	93-0945003
(Commission file number)	(IRS employer identification No.)

585 West 500 South, Bountiful, Utah	84010
(Address of principal executive offices)	(Zip code)

(801) 298-3360

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~[ ] Soliciting ~~2.02.~~material pursuant ~~Results~~to ofRule ~~Operations~~14a-12 ~~and~~under ~~Financial~~the ~~Condition~~Exchange Act (17 CFR 240.14a-12)

On[ ] Pre-commencement communications ~~May~~pursuant 9,to ~~2007,~~Rule ~~Specialized Health Products International, Inc.~~ 14d-2(~~the “Company”~~b) ~~issued~~under ~~a press release announcing financial results for its first quarter ended March 31, 2007. A copy of~~ the ~~press~~Exchange ~~release~~Act is(17 ~~attached hereto as Exhibit 99~~CFR 240.~~1 to this report, and incorporated herein by reference.~~14d-2(b))

~~The~~[ ] Pre-commencement communications ~~Company~~pursuant ~~will conduct a conference call~~ to ~~discuss~~Rule ~~its financial results for its first quarter ended March 31, 2007 on Wednesday, May 9, 2007, at~~ 13e-4~~:30 p.m. Eastern Time. Investors can participate in the conference call live by dialing~~ (~~800~~c) ~~230-1085~~under in the ~~U.S.~~Exchange ~~and (612)~~Act 234-9960 internationally. In addition, the call will be webcast live and available for playback within one hour of completion of the call through a link on the Company’s website at www.shpi.com. A replay of the call will also be available for one week after the event by dialing (~~800)~~17 ~~475-6701 in the U~~CFR 240.~~S. and~~ 13e-4(~~320~~c) ~~365-3844 internationally and entering access code 871947.~~)

Item 9 8.01 Other Information. ~~Financial Statements and Exhibits.~~

In December 2002, Becton Dickinson (d“BD”) ~~Exhibits~~filed ~~Number~~a ~~Description~~lawsuit against Tyco Healthcare in the United States Court of the District of Delaware, asserting that Tyco Healthcare’s Monoject Magellan™ safety products infringe upon BD’s U.S. Patent No. 5,348,544 (‘544 Patent), titled “Single-Handedly Actuable Safety Shield for Needles.” Tyco Healthcare is now known as Covidien. Tyco Healthcare developed the Monoject Magellan™ safety products in association with us. We are not a party to the patent infringement lawsuit.

~~99.1~~On October ~~Press~~26, ~~Release~~2004, ~~dated~~a ~~May~~jury 9,found ~~2007,~~in ~~announcing~~favor ~~the~~of ~~Company~~BD that Tyco Healthcare’s ~~financial~~Monoject Magellan™ ~~results~~safety ~~for~~products ~~its~~willfully ~~first~~infringed ~~quarter~~the ~~ended~~‘544 Patent. On November 1, 2004, the court entered the judgment in favor of BD. Tyco Healthcare challenged the jury finding in post-trial motions. On March 31, ~~2007~~2006, the court granted Tyco Healthcare’s motion for a new trial on the issue of infringement with respect to the ‘544 Patent.

2The new trial commenced on November 27, 2007. On November 30, 2007, a jury found in favor of BD that Tyco Healthcare’s Monoject Magellan™ safety products infringe upon the ‘544 Patent. The court did, however, grant Tyco Healthcare’s motion to dismiss BD’s claims of willful infringement. Tyco Healthcare has indicated that it intends to appeal the jury’s decision following post-trial motions.

~~SIGNATURES~~Under our arrangements with Tyco Healthcare, Tyco Healthcare has the right to withhold up to fifty percent (50%) of royalties due as an offset against litigation expenses related to charges of infringement by a third party for the manufacture, use or sale of licensed product. This right continues while this litigation is pending. If, as a result of judgment in the litigation or settlement with BD, Tyco Healthcare is required to pay royalty and/or other monies to BD, Tyco Healthcare may thereafter deduct from the amount of royalties due us on unit sales of products alleged to infringe, an amount which is the lesser of all royalties and/or other monies paid by Tyco Healthcare to BD, or fifty percent (50%) of all royalty payments otherwise payable to us. Accordingly, we have previously recorded liabilities for amounts that were our estimate of the portion of costs associated with BD’s suit against Tyco Healthcare that Tyco Healthcare would withhold against the royalties due to us.

~~Pursuant~~As of September 30, 2007, there remained $508,409 of the accrued liability which represented our estimate of the portion of costs associated with BD’s suit against Tyco Healthcare that Tyco Healthcare will withhold against future royalties due to us as of that date. Based upon information available at this time, we anticipate the ~~requirements~~litigation will continue into our 2008 fiscal year. Moreover, we intend to take a non-cash charge to income of approximately $250,000 during the ~~Securities~~fourth ~~Exchange~~quarter ~~Act~~of 2007, which together with the balance of our ~~1934~~related accrued liability, is our estimate of the ~~registrant~~portion ~~has~~of ~~duly~~costs associated ~~caused~~with ~~this~~BD’s ~~report~~suit against Tyco Healthcare that Tyco Healthcare will withhold against the royalties due to beus ~~signed~~through onthe ~~its~~end ~~behalf~~of by2008. After this additional accrual, we anticipate our earnings for 2007 will still fall within the ~~undersigned~~range ~~hereunto~~previously ~~duly~~disclosed ~~authorized~~in our financial projections for 2007.

	SPECIALIZED HEALTH PRODUCTS
	INTERNATIONAL, INC.
Date: May 9, 2007	By:	/s/ JEFFREY M. SOINSKI
		Jeffrey M. Soinski
		President, Chief Executive Officer and Director

Forward-Looking Statements

3The statements contained in this Form 8-K, including but not limited to statements regarding (i) Tyco Healthcare’s intention to appeal the jury’s decision, (ii) our intention to take a non-cash charge to income, and (iii) our anticipated performance against financial goals for 2007 and other statements that are not historical facts, are forward-looking statements and are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are based on management’s current expectations, and are subject to risks and uncertainties that could cause actual results to vary materially from historical results or those anticipated in such forward-looking statements. We wish to advise readers that a number of important factors could cause actual results to differ materially from those anticipated in such forward-looking statements. These factors include, but not are limited to, significant fluctuations in future operating results due to a number of economic conditions, risks in product and technology development, developments in the litigation between BD and Tyco Healthcare, the effect of our accounting policies and other risk factors detailed in our filings with the Securities and Exchange Commission, including the Company’s annual report on Form 10-KSB for the fiscal year ended December 31, 2006. These forward-looking statements speak only as of the date on which such statements are made, and we undertake no obligation to update such statements to reflect events or circumstances arising after such date.

~~EXHIBIT INDEX~~2

Exhibit No.	Description of Document
99.1	Press Release, dated May 9, 2007, announcing the Company’s financial results for its first quarter ended March 31, 2007

SIGNATURES

4Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.

Date: December 3, 2007

	By: /s/ Jeffrey M. Soinski Jeffrey M. Soinski President, Chief Executive Officer, Director

Filing Compare · SPECIALIZED HEALTH PRODUCTS INTERNATIONAL INC